Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis

European Journal of Cancer

Volumn 48, Issue 18, 2012, Pages 3499-3513

  Chalkidou, A ^a   Landau, D B ^a   Odell, E W ^b   Cornelius, V R ^c   O'Doherty, M J ^a   Marsden, P K ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Fluorothymidine; Ki 67; Meta analysis; PET; QUADAS; Systematic review

Indexed keywords

3' FLUOROTHYMIDINE F 18; BIOLOGICAL MARKER; KI 67 ANTIGEN;

BIBLIOGRAPHIC DATABASE; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; COCHRANE LIBRARY; CORRELATION COEFFICIENT; DRUG UPTAKE; EMBASE; FISHER EXACT TEST; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MEDLINE; META ANALYSIS; META ANALYSIS (TOPIC); PEER REVIEW; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLISHING; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR GROWTH; VALIDATION STUDY;

EID: 84869507209     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.001     Document Type: Article

References (70)

1. E. de Azambuja, F. Cardoso, and G. de Castro Jr. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients Br J Cancer 96 10 2007 1504 1513 (Pubitemid 46762956)
2. B. Martin, M. Paesmans, and C. Mascaux Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis Br J Cancer 91 12 2004 2018 2025 (Pubitemid 40128768)
3. J.S. Rasey, J.R. Grierson, L.W. Wiens, P.D. Kolb, and J.L. Schwartz Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 9 2002 1210 1217 (Pubitemid 34988769)
4. S. Apisarnthanarax, M.M. Alauddin, and F. Mourtada Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H- fluorothymidine using preclinical tumor models Clin Cancer Res 12 15 2006 4590 4597 (Pubitemid 44297809)
5. A.K. Buck, G. Halter, and H. Schirrmeister Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J Nucl Med 44 9 2003 1426 1431 (Pubitemid 39663355)
6. A.K. Buck, M. Bommer, and S. Stilgenbauer Molecular imaging of proliferation in malignant lymphoma Cancer Res 66 22 2006 11055 11061 (Pubitemid 44877006)
7. D.L. Francis, A. Freeman, and D. Visvikis In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography Gut 52 11 2003 1602 1606 (Pubitemid 37363445)
8. C.S. Yap, J. Czernin, and M.C. Fishbein Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography Chest 129 2 2006 393 401 (Pubitemid 43289860)
9. T. Hatakeyama, N. Kawai, and Y. Nishiyama 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma Eur J Nucl Med Mol Imaging 35 11 2008 2009 2017
10. T. Saga, H. Kawashima, and N. Araki Evaluation of primary brain tumors with FLT-PET: usefulness and limitations Clin Nucl Med 31 12 2006 774 780 (Pubitemid 44789556)
11. D.C. Cobben, P.H. Elsinga, and A.J. Suurmeijer Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine Clin Cancer Res 10 5 2004 1685 1690 (Pubitemid 38435559)
12. S.J. Choi, J.S. Kim, and J.H. Kim [18F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors Eur J Nucl Med Mol Imaging 32 6 2005 653 659
13. W. Chen, T. Cloughesy, and N. Kamdar Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 46 6 2005 945 952 (Pubitemid 43733508)
14. R. Ullrich, H. Backes, and H. Li Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma Clin Cancer Res 14 7 2008 2049 2055 (Pubitemid 351551115)
15. S.D. Richard, B. Bencherif, and R.P. Edwards Noninvasive assessment of cell proliferation in ovarian cancer using [(18)F]3′deoxy-3′- fluorothymidine positron emission tomography/computed tomography imaging Nucl Med Biol 38 4 2011 485 491
16. J.S. Brockenbrough, T. Souquet, and J.K. Morihara Tumor 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of 18F-FLT PET studies in lung tumors J Nucl Med 52 8 2011 1181 1188
17. K.B. Contractor, L.M. Kenny, and J. Stebbing Biological basis of [(1)(1)C]choline-positron emission tomography in patients with breast cancer: comparison with [(1)F]fluorothymidine positron emission tomography Nucl Med Commun 32 11 2011 997 1004
18. S.J. Price, T.D. Fryer, and M.C. Cleij Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F] fluorothymidine positron-emission tomography: An image-guided biopsy study Clin Radiol 64 1 2009 52 63
19. Y. Yamamoto, R. Kameyama, and K. Izuishi Detection of colorectal cancer using 18F-FLT PET: comparison with 18F-FDG PET Nucl Med Commun 30 11 2009 841 845
20. B. Smyczek-Gargya, N. Fersis, and H. Dittmann PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study Eur J Nucl Med Mol Imaging 31 5 2004 720 724 (Pubitemid 38647912)
21. H. Dittmann, B.M. Dohmen, and F. Paulsen [18F]FLT PET for diagnosis and staging of thoracic tumours Eur J Nucl Med Mol Imaging 30 10 2003 1407 1412 (Pubitemid 37247960)
22. E.G. Troost, J. Bussink, and P.J. Slootweg Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity J Nucl Med 51 5 2010 713 719
23. K. Ott, K. Herrmann, and T. Schuster Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer Ann Surg Oncol 18 12 2011 3316 3323
24. R. Kameyama, Y. Yamamoto, and K. Izuishi Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET Eur J Nucl Med Mol Imaging 36 3 2009 382 388
25. A. Linecker, C. Kermer, and I. Sulzbacher Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival Nuklearmedizin 47 2 2008 80 85 (Pubitemid 351700466)
26. H. Hoshikawa, Y. Nishiyama, and T. Kishino Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers Mol Imaging Biol 13 1 2011 172 177
27. H.L. van Westreenen, D.C. Cobben, and P.L. Jager Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer J Nucl Med 46 3 2005 400 404 (Pubitemid 43093146)
28. K. Herrmann, A.K. Buck, and T. Schuster Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment J Nucl Med 52 5 2011 690 696
29. N. Diwakar, M. Sperandio, M. Sherriff, A. Brown, and E.W. Odell Heterogeneity, histological features and DNA ploidy in oral carcinoma by image-based analysis Oral Oncol 41 4 2005 416 422 (Pubitemid 40387871)
30. R. Boellaard Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 Suppl. 1 2009 11S 20S
31. S. Nakasu, Y. Nakasu, T. Fukami, and M. Matsuda Immunohistochemical proliferation markers may overestimate the growth potential after ionizing radiation: in vivo study in the rat anterior pituitary gland Neurol Med Chir (Tokyo) 43 11 2003 521 526 (Pubitemid 37498661)
32. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 2003 25
33. P.F. Whiting, M.E. Weswood, and A.W. Rutjes Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies BMC Med Res Methodol 6 2006 9
34. W. Hollingworth, L.S. Medina, and R.E. Lenkinski Interrater reliability in assessing quality of diagnostic accuracy studies using the QUADAS tool. A preliminary assessment Acad Radiol 13 7 2006 803 810 (Pubitemid 43866523)
35. Reitsma JB, Rutjes AW, Whiting PF, Vlassov VV, Leeflang MG, Deeks JJ. Chapter 9: Assessing methodological quality. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0, The Cochrane Collaboration 2009.
36. P.F. Whiting, A.W. Rutjes, and M.E. Westwood QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies Ann Intern Med 155 8 2011 529 536
37. M.M. Leeflang, J.J. Deeks, C. Gatsonis, and P.M. Bossuyt Systematic reviews of diagnostic test accuracy Ann Intern Med 149 12 2008 889 897
38. P. Whiting, R. Harbord, and J. Kleijnen No role for quality scores in systematic reviews of diagnostic accuracy studies BMC Med Res Methodol 5 2005 19
39. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 11 2002 1539 1558 (Pubitemid 34746062)
40. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188 (Pubitemid 17189972)
41. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634 (Pubitemid 27387172)
42. F. Eckel, K. Herrmann, and S. Schmidt Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine J Nucl Med 50 9 2009 1441 1447
43. Y. Yamamoto, Y. Nishiyama, and S. Ishikawa Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 10 2007 1610 1616 (Pubitemid 47476919)
44. L.M. Kenny, D.M. Vigushin, and A. Al-Nahhas Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods Cancer Res 65 21 2005 10104 10112 (Pubitemid 41541493)
45. A.K. Buck, H. Schirrmeister, and M. Hetzel 3-Deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules Cancer Res 62 12 2002 3331 3334 (Pubitemid 34651372)
46. M. Wagner, U. Seitz, and A. Buck 3′-[18F]fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease Cancer Res 63 10 2003 2681 2687 (Pubitemid 36605213)
47. H. Vesselle, J. Grierson, and M. Muzi In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors Clin Cancer Res 8 11 2002 3315 3323 (Pubitemid 35340704)
48. M. Muzi, H. Vesselle, and J.R. Grierson Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer J Nucl Med 46 2 2005 274 282 (Pubitemid 43073435)
49. E.G. Troost, W.V. Vogel, and M.A. Merkx 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients J Nucl Med 48 5 2007 726 735 (Pubitemid 47604972)
50. L.B. Been, A.J. Suurmeijer, and P.H. Elsinga 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas J Nucl Med 48 3 2007 367 372 (Pubitemid 47604918)
51. H. Backes, R. Ullrich, and B. Neumaier Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma Eur J Nucl Med Mol Imaging 36 12 2009 1960 1967
52. N. Kawai, M. Kagawa, and K. Miyake Use of 11F-fluorothymidine positron emission tomography in brain tumor No Shinkei Geka 37 7 2009 657 664
53. C. Pfannenberg, P. Aschoff, and H. Dittmann PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 51 6 2010 845 853
54. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol 62 10 2009 e1 e34
55. P.P. Goodell, A.M. Krasinskas, J.M. Davison, and D.J. Hartman Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors Am J Clin Pathol 137 4 2012 576 582
56. P.J. van Diest, P. van Dam, and S.C. Henzen-Logmans A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group J Clin Pathol 50 10 1997 801 804 (Pubitemid 27475783)
57. P.J. Schleyer, M.J. O'Doherty, and P.K. Marsden Extension of a data-driven gating technique to 3D, whole body PET studies Phys Med Biol 56 13 2011 3953 3965
58. R. Simon, M. Mirlacher, and G. Sauter Tissue microarrays in cancer diagnosis Expert Rev Mol Diagn 3 4 2003 421 430 (Pubitemid 36859290)
59. J. Fernebro, J. Engellau, A. Persson, A. Rydholm, and M. Nilbert Standardizing evaluation of sarcoma proliferation- higher Ki-67 expression in the tumor periphery than the center APMIS 115 6 2007 707 712 (Pubitemid 46854996)
60. W. Muller, A. Schneiders, S. Meier, G. Hommel, and H.E. Gabbert Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma Br J Cancer 74 5 1996 759 765 (Pubitemid 26300768)
61. S. Moertel, H. Ackermann, and M. Baghi Heterogeneity of primary site biopsies in head and neck squamous cell carcinoma Anticancer Res 31 2 2011 665 669
62. J. Tolles, Y. Bai, and M. Baquero Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma Breast Cancer Res 13 3 2011 R51
63. F. Tixier, C.C. Le Rest, and M. Hatt Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer J Nucl Med 52 3 2011 369 378
64. J.F. Eary, F. O'Sullivan, J. O'Sullivan, and E.U. Conrad Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome J Nucl Med 49 12 2008 1973 1979
65. R. Boellaard, N.C. Krak, O.S. Hoekstra, and A.A. Lammertsma Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study J Nucl Med 45 9 2004 1519 1527 (Pubitemid 47618506)
66. Y.E. Erdi, S.A. Nehmeh, and T. Pan The CT motion quantitation of lung lesions and its impact on PET-measured SUVs J Nucl Med 45 8 2004 1287 1292 (Pubitemid 47618524)
67. R. Boellaard, M.J. O'Doherty, and W.A. Weber FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 1 2010 181 200
68. NCRI PET Research Network. http://www.ncri-pet.org.uk/; [accessed 21.02.12].
69. American College of Radiology Imaging Network. http://www.acrin.org/; [ accessed 21.02.12].
70. M. Dowsett, T.O. Nielsen, and R. A'Hern Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group J Natl Cancer Inst 103 22 2011 1656 1664